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CASE REPORT

LMNA Gene Mutation Presenting with Ventricular
Tachycardia in the Absence of
Dilated Cardiomyopathy
Binod Poudel a,*, Shreeja Shah a, Shristi Khanal a,
Muhammad A. A. Cheema b, Bikash Basyal a
a
b

Department of Medicine, Abington Jefferson Health, Abington, PA, USA
Division of Cardiology, Thomas Jefferson University, Philadelphia, PA, USA

Abstract
Genetic mutations can present with cardiomyopathies and ventricular arrhythmias in young population in the absence
of other cardiac risk factors. LMNA genetic mutation is one of the causes of dilated cardiomyopathy (DCM) which can
present with conduction abnormalities and arrhythmias. We present a case of LMNA genetic mutation in an African
American male who presented with ventricular tachycardia in the absence of dilated cardiomyopathy initially
mimicking cardiac sarcoidosis. Diagnostic challenges included initial impression of cardiac sarcoidosis as suggested by
cardiac MRI, but negative tissue pathology on endomyocardial biopsy and negative activity on FDG PET scan. Treatment involved initiation of beta blocker and an implantable cardiac deﬁbrillator placement for secondary prevention.
Keywords: LMNA gene, Ventricular tachycardia, Dilated cardiomyopathy, Cardiac sarcoidosis, Nuclear lamins, Genetic
testing

1. Introduction

V

entricular tachycardia (VT) is a serious and
potentially fatal cause of sudden cardiac
death. It can result from structural defects in the
myocardium from various ischemic or non-ischemic
causes. In younger population with no overt cardiac
history, VT can be an initial presentation of cardiomyopathy.1 In addition to cardiomyopathies, VTs
can occur in the setting of inﬁltrative diseases,
channelopathies or other inherited genetic conditions. Evaluation of VT begins with workup for
coronary artery disease followed by search for other
less common etiologies.
Sarcoidosis is an inﬂammatory multisystemic
disease of unknown etiology that is characterized by
presence of non-caseating granulomas in various
organ systems.2 It can have various clinical manifestations in different organ systems but itmost
commonly involves the lungs. However, the disease
can have varied presentation with involvement of

any organ including liver, skin, or eyes.3 The cardiac
manifestations of sarcoidosis result from granulomatous inﬁltration of cardiac muscles which can
manifest with cardiomyopathy, congestive heart
failure or ventricular arrhythmia. Conduction disorders leading to heart block can also occur with AV
nodal involvement.4 Cardiac sarcoidosis can remain
undiagnosed in cases where other systemic manifestations of sarcoidosis are absent.
In addition to inﬁltrative diseases, genetic mutations can also lead to cardiomyopathy and cardiac
arrhythmias. Mutation in LMNA gene, that codes
for type A nuclear lamins (Lamin A and C) are one
of the most commonly discovered genetic mutations
in work up of dilated cardiomyopathies.5,6
Screening for genetic mutations is important in
cases where workup is unrevealing since presence
of such mutations can help in recommending genetic screening for family members.7
We present a case of a young African American
male who presented with ventricular tachycardia
which was initially thought to be from cardiac
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sarcoidosis. Further workup including endomyocardial biopsy and PET scan were not suggestive of
cardiac sarcoidosis and genetic testing revealed
mutation in LMNA gene. We present the diagnostic
challenges and the dilemma in ﬁnding the cause of
ventricular arrhythmia.

2. Case description
A 33-year-old African American man presented to
the emergency department (ED) with the complaint
of chest pain along with shortness of breath while
taking a shower at home. He didn't have any past
medical or surgical history and worked as a
schoolteacher. He had no known family history of
any heart disease. He had played basketball and
football during high school with no issues.
In the ED, he was noted to be tachycardic with
heart rate 119/min. The rest of his vital signs were
blood pressure 123/87 mmHg and respiratory rate
18/min. Laboratory investigations were within
normal limits with a normal renal and liver function
tests and a complete blood count was within normal
limits. A urine drug screen was positive for opiates,
benzodiazepines and cannabinoids.
He developed palpitations in the ED, during which
an electrocardiogram (ECG) showed a wide complex
tachycardia with heart rate of 240/minute (Fig. 1). He
was administered 6mg adenosine which was followed
by second dose of 12mg adenosine which did not
terminate the arrhythmia. He received 150mg of
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Amiodarone with no response. This was followed by
another 150mg after which his ECG revealed a
normal sinus rhythm. He was maintained on an
Amiodarone drip and admitted to the cardiac critical
care unit (CCU) for closer monitoring.
On hospital day 1, he developed bradycardia with
ECG revealing sinus bradycardia with heart rate 44/
minute (Fig. 2). Amiodarone drip was discontinued.
An echocardiogram showed normal left ventricular
(LV) function with normal ejection fraction. He underwent cardiac catheterization which did not
reveal any coronary abnormalities or obstruction. A
cardiac magnetic resonance imaging (MRI) was
done which showed multiple patchy areas of midwall late gadolinium enhancement particularly
prominent as transmural enhancement in the
inferolateral mid myocardium (Fig. 3). He was
started on pindolol and was evaluated by electrophysiological cardiologist for implantable cardiac
deﬁbrillator (ICD). A high-resolutioncomputerized
tomography (CT) of chest done with contrast did not
show any reticular opacities in lung parenchyma or
hilar adenopathy. An endomyocardial biopsy was
done which was negative for myocarditis or any
granulomatous disease, and Congo Red stain was
negative for amyloidosis. Serum angiotensinogen
converting enzyme (ACE) level was 35 U/L (within
normal limits). He underwent an ICD placement for
secondary prevention of ventricular arrhythmias
and was discharged from the hospital with a plan to
pursue a positron emission tomography (PET) scan

Fig. 1. Initial ECG in the ED showing ventricular tachycardia.
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Fig. 2. EKG on day 1 showing bradycardia.

Fig. 3. Patchy areas of mid wall late gadolinium enhancement particularly prominent as transmural enhancement in the inferolateral mid
myocardium (red arrow).

as an outpatient and discuss further treatment
options.
As an outpatient, he underwent a PET scan which
did not show any tracer activity in the myocardium
or any evidence of cardiac sarcoidosis. He was also
evaluated by Ophthalmologist and was not found to
have any manifestations of ocular sarcoidosis. He
was referred for genetic testing which revealed
heterozygous mutation in LMNA gene. Interrogation of his ICD did not show any further VT in
subsequent ofﬁce visit and his family members
including children were recommended to get genetic testing for screening.
In the absence of other identiﬁable etiology and a
known association of LMNA gene mutation with
ventricular arrhythmia, we think the VT in this
young patient is due to LMNA gene mutation.

3. Discussion
LMNA gene encodes Lamin A and Lamin C which
are structural proteins of nuclear lamina. Mutation
in this gene can manifest either as isolated muscular
dystrophy, isolated cardiomyopathy or a combination of both.8 LMNA gene mutations have been
linked to Emery-Dreifuss muscular dystrophy and
other rare forms of muscular dystrophies like limb
girdle muscular dystrophy.9 LMNA related cardiomyopathy can present with symptomatic conduction system disease, arrhythmias, or with symptoms
of heart failure.8 LMNA related cardiomyopathy is
an autosomal dominant disorder with age dependent penetrance with onset in the third and fourth
decade and more than 90% penetrance by the 7th
decade.10 The frequency of LMNA gene mutation
has been found to be as high as 8% in patients with
familial dilated cardiomyopathies.11 Ventricular
arrhythmia or sudden cardiac death can sometimes
be the presenting manifestation even in the absence
of underlying systolic dysfunction.12 In one longitudinal retrospective observational study including
27 families with 164 members, 94 had LMNA gene
mutation and among them 60 were phenotypically
affected. Out of the 60, 40 had DCM with AV Block
(AVB), 12 had DCM with ventricular arrhythmias, 6
had DCM, AVB and Emery-Dreifuss muscular
dystrophy type 2 (EDMD2) and 2 had AVB with
EDMD2.10
LMNA sequence analysis identiﬁes pathogenic
variants in most individuals with LMNA-related
DCM. It should be suspected in individuals with a
clinical diagnosis of idiopathic DCM (etiology not
attributed to coronary artery disease, structural
heart disease, or other conditions that may cause
DCM), almost always in the setting of conduction
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system disease and/or supraventricular or ventricular arrhythmias.
Management of genetic cardiomyopathies
including LMNA related CMP involves referral to
centers with special expertise in cardiovascular genetic medicine. With an established arrhythmia or
known risk of arrhythmia, ICD implantation is
advised before the ejection fraction falls below
35%.12 If patients develop atrial ﬁbrillation, cardioversion is advised. Patients unresponsive to cardioversion are treated with anticoagulants and
agents for ventricular rate control.
Screening and identiﬁcation of DCM before the
onset of symptoms enables the initiation of medical
therapy that may delay disease progression. Individuals with an LMNA pathogenic variant who
are found to have any ECG abnormality should
undergo a cardiovascular evaluation for disease
progression at least. This should include, minimally,
an ECG, 24- or 48-hour rhythm monitoring, and
measurement of ventricular function.
When the LMNA pathogenic variant has been
identiﬁed in a family, molecular genetic testing can
be offered to relatives at risk in order to facilitate
prompt diagnosis, surveillance, and treatment in
those in whom the LMNA pathogenic variant has
been detected.
Our patient had presented with chest discomfort
and in the absence of any prior cardiac disease, his
initial arrhythmia was wide complex tachycardia
which was ventricular tachycardia. Extensive workup
did not reveal any cause of cardiomyopathy. Genetic
testing revealed LMNA related cardiomyopathy.
Surprisingly, his echocardiogram showed normal left
ventricular dimensions. Most of the LMNA related
cardiomyopathy cases show increased left ventricular
dimension. Our case was unique in the sense that LV
dimensions were within the normal limits.

4. Conclusion
Despite the advancement in imaging techniques,
establishing a deﬁnite etiology for VT is challenging.
LMNA-related cardiomyopathy should be in differential diagnosis of idiopathic cardiomyopathy.
Sometimes this cardiomyopathy can present
without LV dilation. Screening and identiﬁcation of
LMNA related cardiomyopathy before the onset of
symptoms enables the initiation of medical therapy
that may delay disease progression.
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